Literature DB >> 7690775

Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin.

S Nonoyama1, M Farrington, H Ishida, M Howard, H D Ochs.   

Abstract

Most patients with common variable immunodeficiency (CVI) have normal numbers of circulating B cells but low concentrations of serum Ig. To determine if the hypogammaglobulinemia is caused by an intrinsic B cell defect, we studied B cell function of 22 CVI patients. Cultured B cells from all CVI patients underwent normal proliferation and synthesized normal quantities of IgE in the presence of anti-CD40 and IL-4. If cultured with anti-CD40 and IL-10, four patterns of Ig isotype synthesis were observed. Six CVI patients produced normal amounts of IgM, IgG, and IgA. Four patients produced normal quantities of IgM and IgG. Of the remaining 12 patients who failed to synthesize IgG and IgA, 8 produced normal and 4 synthesized decreased amounts of IgM. Analysis of the IgG subclasses produced by 10 patients with IgG-secreting B cells revealed that IgG4 was the most affected subclass, followed by IgG2; synthesis of IgG3 and IgG1 remained normal. Similarly, in the six IgA producing patients, IgA2 was more often affected than IgA1. The hierarchy of Ig isotype and subclass synthesis corresponds to Ig heavy chain constant region gene location on chromosome 14. Thus, circulating B cells of CVI patients are committed to synthesize one or more Ig isotypes or subclasses, and under proper conditions can proliferate, mature into Ig-secreting cells, and undergo class switch to IgE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690775      PMCID: PMC288269          DOI: 10.1172/JCI116701

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

Review 1.  Circulating B-cells in patients with immunodeficiency.

Authors:  M D Cooper; A R Lawton
Journal:  Am J Pathol       Date:  1972-12       Impact factor: 4.307

2.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

3.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.

Authors:  J Banchereau; P de Paoli; A Vallé; E Garcia; F Rousset
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

4.  CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation signal directly to human B cells for IgE production.

Authors:  K Zhang; E A Clark; A Saxon
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

5.  Effect of 12,13-phorbol dibutyrate and ionomycin on defective B cells in common variable immunodeficiency.

Authors:  A Franz; A Bryant; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

7.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  Human low molecular weight B cell growth factor induces surface IgM+/A- B cells to express and secrete IgA.

Authors:  J N Bertolini; J Bertolini; E Thean; E M Benson
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

9.  Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells.

Authors:  H Ishida; R Hastings; J Kearney; M Howard
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A.

Authors:  T Defrance; B Vanbervliet; F Brière; I Durand; F Rousset; J Banchereau
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

3.  Role of B cells in common variable immune deficiency.

Authors:  Sam Ahn; Charlotte Cunningham-Rundles
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 4.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 5.  Study of patients with Hyper-IgM type IV phenotype who recovered spontaneously during late childhood and review of the literature.

Authors:  Neslihan Edeer Karaca; Anne Durandy; Nesrin Gulez; Guzide Aksu; Necil Kutukculer
Journal:  Eur J Pediatr       Date:  2011-01-28       Impact factor: 3.183

6.  Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination.

Authors:  Kohsuke Imai; Nadia Catalan; Alessandro Plebani; László Maródi; Ozden Sanal; Satoru Kumaki; Vasantha Nagendran; Philip Wood; Catherine Glastre; Françoise Sarrot-Reynauld; Olivier Hermine; Monique Forveille; Patrick Revy; Alain Fischer; Anne Durandy
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID).

Authors:  C Groth; R Drager; K Warnatz; G Wolff-Vorbeck; S Schmidt; H Eibel; M Schlesier; H-H Peter
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

8.  B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis.

Authors:  A Saxon; B Keld; D Diaz-Sanchez; B C Guo; N Sidell
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

9.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients.

Authors:  V Thon; H M Wolf; M Sasgary; J Litzman; A Samstag; I Hauber; J Lokaj; M M Eibl
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.